Calamos Advisors
CSTL icon

Calamos Advisors’s Castle Biosciences CSTL Stock Holding History

Calamos Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-38,876
Closed -$1.01M – 1255
2022
Q3 		$1.01M Buy
+38,876
New +$1.09M ﹤0.01% 941
2021
Q4 		– Sell
-131,984
Closed -$8.78M – 1128
2021
Q3 		$8.78M Buy
131,984
+17,377
+15% +$1.22M 0.04% 465
2021
Q2 		$8.4M Buy
114,607
+8,846
+8% +$584K 0.04% 448
2021
Q1 		$7.24M Sell
105,761
-41,075
-28% -$3.09M 0.04% 420
2020
Q4 		$9.86M Sell
146,836
-4,756
-3% -$258K 0.06% 337
2020
Q3 		$7.8M Buy
151,592
+29,207
+24% +$1.3M 0.05% 364
2020
Q2 		$4.61M Buy
122,385
+34,681
+40% +$1.18M 0.03% 465
2020
Q1 		$2.61M Sell
87,704
-14,789
-14% -$446K 0.02% 506
2019
Q4 		$3.52M Buy
102,493
+70,845
+224% +$1.73M 0.02% 563
2019
Q3 		$572K Buy
+31,648
New +$702K ﹤0.01% 687

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Calamos Advisors's CSTL Position: Q4 2022 in Review

Calamos Advisors sold out of Castle Biosciences (CSTL) in Q4 2022, closing a stake of 38,876 shares — an estimated $1.01M sold.

Calamos Advisors first reported a position in CSTL in Q3 2019 and held it in 10 quarters. The position peaked at $9.86M in Q4 2020. 153 funds tracked by Wall St. Rank hold CSTL as of Q4 2022.

  • Calamos Advisors reported no remaining Castle Biosciences position as of Q4 2022 after selling out during the quarter.
  • Calamos Advisors sold 38,876 Castle Biosciences shares in Q4 2022, an estimated $1.01M.
  • Calamos Advisors first reported a position in Castle Biosciences in Q3 2019 and held it in 10 quarters.
  • Calamos Advisors's Castle Biosciences position peaked at $9.86M in Q4 2020.
  • 153 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2022.

Based on Calamos Advisors's 13F filing for Q4 2022, filed 26 Jan 2023.